Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Current and Emerging Immunotherapies in SCLC: Promise and Challenges

Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based

Activity Overview

This continuing medical education (CME) activity is designed to inform physicians about the emerging role of immunotherapy in the treatment of small cell lung cancer (SCLC).

Benefits of Participating

  • Learn expert perspectives on the best strategies for combining immunotherapy with chemotherapy for the treatment of SCLC patients
  • Integrate the results of the latest clinical studies into your practice decisions
  • Explain safety considerations of chemo-immunotherapy combination therapy in SCLC
  • Outline the latest strategies for the use of immunotherapy in patients with previously treated SCLC

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • To receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe the benefit of adding immunotherapy to first-line chemotherapy for SCLC
  • Discuss the safety of first-line chemo-immunotherapy combination therapy in SCLC
  • Analyze the efficacy of immunotherapy in patients with previously treated SCLC

Faculty, Staff, and Planners’ Disclosures


Stephen V. Liu
Stephen V. Liu, MD
Associate Professor of Medicine
Director, Thoracic Oncology
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Washington, DC

Disclosures: Grant/Research Support: Alkermes, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Clovis Oncology, Corvus Pharmaceuticals, Debiopharm, Esanex, Genentech/Roche, Ignyta, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Pfizer, Rain Therapeutics; Consultant: Apollomics, AstraZeneca, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech, Guardant Health, Heron Therapeutics, Ignyta, Inivata, Janssen, Lilly, LOXO Oncology, Merck, MSD, Pfizer, PharmaMar, Regeneron, Roche, Taiho, Takeda/Ariad, Tempus.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

This activity is funded by PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By